Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
Earnings Neutral

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

NurExone Extends Runway Amid Rising Burn Rate as IND Prep Continues

By The Northwire Desk — AI Analysis Apr 16, 2026 · 09:15 NRX · 0.65 NurExone Biologic Inc.
Executive Summary

Financial Performance and Liquidity

  • Net Loss: Reported US$6.38 million for FY 2025, an increase from US$5.04 million in FY 2024.
  • Q4 2025 Net Loss: US$1.40 million.
  • Cash Position: Total cash and equivalents of US$2.14 million as of December 31, 2025, up from US$0.70 million in FY 2024.
  • Financing: Approximately US$5.9 million raised through private placements and warrant exercises during 2025.
  • Accumulated Deficit: US$25.48 million as of December 31, 2025.
Material Impact

Liquidity vs. Burn Rate Analysis

  • Positive: Cash position tripled from US$0.70 million to US$2.14 million, extending operational runway by approximately 3-5 months at current burn rates.
  • Negative: Net loss widened by ~26% year-over-year (US$1.34M increase), indicating higher capital consumption without revenue generation.
  • Neutral: Financing activities were incremental and expected given the history of private placements throughout 2025; no surprise capital injection.
NRX · Price
Company Overview

Corporate Profile

  • Company Name: NurExone Biologic Inc. (TSXV: NRX).
  • Flagship Project: ExoPTEN, an exosome-siRNA candidate targeting acute spinal cord injury and optic nerve damage.
  • Platform: Proprietary BM-MSC-derived exosomes with patented 3-D shear-force production technology.
Read the original news release →

More from NurExone Biologic Inc.

Jun 30, 2026 · 08:31

Dilutive financing at a discount underscores cash burn concerns in pre-revenue exosome developer

Financings Jun 24, 2026 · 17:01

Early-stage exosome developer secures Mexican distribution MOU while navigating a tight cash runway and going concern warning.

M&A / Property Jun 01, 2026 · 08:02

NurExone Advances Preclinical Milestones and Secures Minor Capital, But Cash Runway Narrows as Burn Rate Accelerates

Earnings May 19, 2026 · 16:04

NurExone Expands IP Portfolio with South Korea Patent Grant Amidst Manufacturing Push

Other May 14, 2026 · 16:05

NurExone’s EU Program Nod Underscores Exosome Platform’s Promise, But Cash Burn Keeps Investors on Edge

Other Apr 27, 2026 · 16:03

Patent Portfolio Expansion Masks Underlying Liquidity Constraints in Exosome Developer

M&A / Property